ReviewBritish journal of clinical pharmacology2011
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.
Review in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 72 citations in OpenAlex.
- Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.BioMed research international · 2016Trial
- Evaluation of clopidogrel responsiveness using the Platelet Function Analyzer-200 (PFA-200) in dogs.Frontiers in veterinary science · 2025Article
- Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital.Journal of thrombosis and thrombolysis · 2025Article
- Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.Future cardiology · 2024Review
- Evaluation of clopidogrel response in healthy cats using a novel viscoelastic test and thromboelastography.Frontiers in veterinary science · 2024Article
- Retreatment of previously flow diverted intracranial aneurysms with the pipeline embolization device.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2023Article
- Potentially Harmful Drug-Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study.Drugs - real world outcomes · 2023Article
- Evaluation of thrombin generation in dogs administered clopidogrel.Frontiers in veterinary science · 2023Article
- A review of technological innovations leading to modern endovascular brain aneurysm treatment.Frontiers in neurology · 2023Review
- Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2022Review
- Platelet aggregometry for hip fracture surgery in patients treated with clopidogrel: a pilot study.Journal of clinical monitoring and computing · 2022Observational
- Pipeline embolization of proximal middle cerebral artery aneurysms: A multicenter cohort study.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2022Article
- Post-ST-Segment-Elevation Myocardial Infarction Platelet Reactivity Is Associated With the Extent of Microvascular Obstruction and Infarct Size as Determined by Cardiac Magnetic Resonance Imaging.Journal of the American Heart Association · 2022Article
- Pipeline embolization of distal posterior inferior cerebellar artery aneurysms.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2021Article
- Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel.Journal of neurointerventional surgery · 2021Article
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy.Pharmacology research & perspectives · 2020Review
- Black Sorghum Phenolic Extract Modulates Platelet Activation and Platelet Microparticle Release.Nutrients · 2020Article
- Microfluidics in Haemostasis: A Review.Molecules (Basel, Switzerland) · 2020Review
- Polyphenols: Modulators of Platelet Function and Platelet Microparticle Generation?International journal of molecular sciences · 2019Review
- [Evaluation of PFA P2Y assay in monitoring platelet function in elderly patients with cardiovascular disease receiving clopidogrel treatment].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous clinical studies have shown heterogeneity in individual patient responses to antiplatelet therapy and high residual platelet reactivity is associated with increased risk of adverse clinical events. Monitoring response to antiplatelet therapy and tailoring treatment accordingly is currently not recommended in routine clinical practice largely due to the lack of a standardized definition of antiplatelet therapy hyporesponse and the need for a widely accepted point-of-care platelet function test that can be reliably utilized in frontline clinical practice. Recent data have shown that titrating the dose of clopidogrel in patients undergoing percutaneous coronary intervention significantly reduces the incidence of major adverse cardiovascular events and large-scale clinical trials are currently underway to investigate whether individually tailored treatment based on results of platelet function testing leads to improved clinical outcome. Furthermore, genetic testing has demonstrated a link between CYP2C19 genetic polymorphisms, altered clopidogrel metabolite concentrations and adverse clinical events. Clinical studies are currently underway to investigate the potential clinical benefit associated with genotype-guided tailoring of antiplatelet therapy. With the advent of newer, more potent antiplatelet agents and their associated increased bleeding risks, it will become imperative in the future to select the most appropriate, safe and effective drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.